Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the area needed.</li><li> The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.

NRXBF: Tremendous Progress Made in Groundbreaking Treatment

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

<div><ul><li>NurExone is a biopharma company focused on developing regenerative exosome-based therapies for central nervous system injuries. </li><li>Its lead development candidate, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets.</li><li>Introducing Dr. Lior Shaltiel and Yoram Drucker. </li></ul></div>

NurExone is a biopharma company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead development candidate, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets.Introducing Dr. Lior Shaltiel and Yoram Drucker. 

NurExone Biologic's Revolutionary Approach to Nerve Repair - 31 October 2025

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company announced that tests on its signature product, ExePTEN, showed that it produced a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company announced that tests on its signature product, ExePTEN, showed that it produced a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma.

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company announced that the US Patent Office has issued a Notice of Allowance for a patent covering NurExone's proprietary process for producing exosomes-further validating the uniqueness of the product and securing the right to it.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company announced that the US Patent Office has issued a Notice of Allowance for a patent covering NurExone's proprietary process for producing exosomes-further validating the uniqueness of the product and securing the right to it.

NRXBF: US Patent Awarded for Cell Technology

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company announced independent study results that show its exosomes delivered more than twice the amount of wound-healing signals than the industry benchmark.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company announced independent study results that show its exosomes delivered more than twice the amount of wound-healing signals than the industry benchmark.

NRXBF: Company Treatment Outperforms Industry Standard

Israel

NurExone Biologic Inc. operates as a biotech company. The Company develops novel, biologic, and minimal-invasive treatment for spinal cord injury and traumatic brain injury. NurExone Biologic serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nurexone Biologic (NRXBF US)

NRXBF: Tremendous Progress Made in Groundbreaking Treatment

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NurExone Biologic's Revolutionary Approach to Nerve Repair - 31 October 2025

NurExone is a biopharma company focused on developing regenerative exosome-based therapies for central nervous system injuries.

Water Tower Research

NRXBF: Test Results Show Vision Recovery

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: US Patent Awarded for Cell Technology

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: Company Treatment Outperforms Industry Standard

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)